Technology Assessment: Report on the Relative Efficacy of Oral Cancer Therapy for Medicare Beneficiaries Versus Currently Covered Therapy, Part 2. Imatinib for Gastrointestinal Stromal Tumors (GISTs). Table 3

You Are Here: AHRQ Archive Home > Technology Assessment Archive > Report on the Relative Efficacy of Oral Cancer Therapy for Medicare Beneficiaries Versus Currently Covered Therapy

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to www.ahrq.gov for current information.

Table 3. Details of Included Studies

Study No.	First Author, Year	Phase	Report Type	Quality	Comments
*Imatinib Efficacy Studies*
1	van Oosterom, 2001⁶	I/II	Full report	3/5	Main results
1	van Oosterom, 2002⁴⁵	III	Full report	3/5	Followup efficacy data for van Oosterom, et al. 2001
2	Demetri, 2002⁴⁶	II	Full report	5/5	Main results
2	Dagher 2002⁴³	II	Full report	5/5	FDA approval summary with review of Demetri, et al. 2002 data
2	Heinrich, 2003⁴⁷	II	Full report	6/6	followup efficacy data for Demetri, et al. 2002
3	Verweij, 2003⁴⁸	II	Full report	6/6	Main results
4	Verweij, 2004⁴⁹	III	Full report	6/6	Main results
4	Zalcberg, 2004⁵⁰	II	Abstract	Unk	Followup efficacy data for Verweij, et al. 2004
5	Casali, 2004⁵¹	II	Abstract	Unk	Early results of phase II trial
6	Blay, 2004⁵²	III	Abstract	Unk	Early results of phase III trial
7	Rankin, 2004⁵³	III	Abstract	Unk	Early results of phase III trial
7	Patel, 2003⁵⁴	III	Abstract (published 2003 abstract plus commentary)	Unk	Early results of Rankin, et al. 2004 Phase III trial
*Imatinib Plus Surgery Efficacy Studies*
8	Bumming, 2003⁵⁵	II	Full report	4/6	Main results
9	Rutkowski, 2003⁵⁶	Retro	Full report	1/6	Main results
10	Scaife, 2003⁵⁷	Retro	Full report	2/5	Main results
11	Wu, 2003⁵⁸	Retro	Full report	1/6	Main results
*Adverse Events/harm*
1	van Oosterom, 2001⁶	I/II	Full report	3/5	Adverse event data reported within main results full report
1	van Oosterom, 2002⁴⁵	III	Full report	3/5	followup adverse event data for van Oosterom, et al. 2001
2	Demetri, 2002⁴⁶	II	Full report	5/5	Adverse event data reported within main results full report
2	Dagher 2002⁴³	II	Full report	5/5	FDA approval summary with review of Demetri, et al. 2002 data
3	Verweij, 2003⁴⁸	II	Full report	6/6	Adverse event data reported within main results full report
4	Verweij, 2004⁴⁹	III	Full report	6/6	Adverse event data reported within main results full report
*Predictors—tumor characteristics*
1	Debiec-Rychter, 2004⁵⁹	I/II	Full report	6/6	Molecular predictors, sub-study of van Oosterom, et al. 2001
2	Frolov, 2003⁶⁰	II	Full report	1/6	Molecular predictors, sub-study of Demetri, et al. 2002
2	Heinrich, 2003⁴⁷	II	Full report	6/6	Molecular predictors, sub-study of Demetri, et al. 2002
3	Verweij, 2003⁴⁸	II	Full report	6/6	Other predictors reported within main results full report
*Predictors—radiological findings*
1	Stroobants, 2003⁶¹	I/II	Full report	4/6	Radiological predictors, sub-study of van Oosterom, et al. 2001
12	Antoch, 2004⁶²	Pros	Full report	5/5	Radiological predictors study
13	Gayed, 2004⁶³	Pros	Full report	1/5	Radiological predictors study
14	Di Giorgi, 2004⁶⁴	Pros	Abstract	Unk	Radiological predictors study
15	Laussau, 2004⁶⁵	Pros	Abstract	Unk	Radiological predictors study
*Predictors—other clinical factors*
2	Heinrich, 2003⁴⁷	II	Full report	6/6	Other predictors, sub-study of Demetri, et al. 2002
4	Verweij, 2004⁴⁹	III	Full report	6/6	Other predictors reported within main results full report

Abbreviations: Retro = retrospective; Unk = unknown; Pros = prospective

Return to Document

The information on this page is archived and provided for reference purposes only.